TransCode Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying
Portfolio Pulse from Lisa Levin
Insiders at TransCode Therapeutics, Lexicon Pharmaceuticals, and Global Clean Energy Holdings have recently made significant purchases of their respective companies' shares. TransCode Therapeutics published new data supporting the use of TTX-MC138 for metastatic breast cancer treatment, Lexicon Pharmaceuticals announced the pricing of a $125 million public offering and concurrent private placement, and Global Clean Energy signed a $30 million USDA climate-smart commodities grant for its camelina project.
June 23, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Global Clean Energy Holdings 10% owner Michael Zilkha acquired 302,191 shares at an average price of $0.75, after the company signed a $30 million USDA climate-smart commodities grant for its camelina project.
The 10% owner's purchase of shares indicates confidence in the company's prospects following the signing of a $30 million USDA grant for its camelina project. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Lexicon Pharmaceuticals CEO Lonnel Coats acquired 40,000 shares at an average price of $2.31, after the company announced the pricing of a $125 million public offering and concurrent private placement.
The CEO's purchase of shares indicates confidence in the company's prospects following the announcement of a $125 million public offering and concurrent private placement. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
TransCode Therapeutics CEO Michael Robert Dudley acquired 18,607 shares at an average price of $2.62, following the publication of new data supporting the use of TTX-MC138 for metastatic breast cancer treatment.
The CEO's purchase of shares indicates confidence in the company's prospects, especially following the publication of new data supporting their treatment for metastatic breast cancer. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100